 Many other neurotechnologies that have been developed for treating brain dysfunction have primary or side effects that affect some aspect of what we may think of as related to human agency (Zuk et al., 2018). The ethical issues that arise with these neurotechnologies involve determining 1) in which way they do impact our selves or our agency; 2) what value, positive or negative we should put on this impact (or ability to so affect agency); and 3) how to weigh the positive gains against the negatives. One issue that has been raised is whether we possess a clear enough conception of the elements of agency in order to effectively perform this sort of analysis (Roskies, 2015). Moreover, given the likelihood that no objective criteria exist for how to evaluate tradeoffs in these elements, and the fact that different people may value different aspects of themselves differently, the weighing process will likely have to be subjectively relativized.